Skip to main content
Funded Studies

Anthony Stewart Campbell, PhD

Chief Executive Officer and Head of Research & Development at Axial Therapeutics, Inc.

Location: Woburn, MA United States

Dr. Campbell joined Axial Therapeutics in 2017 as vice president of R&D and was promoted to CEO in February 2021. During his 28-year career, Dr. Campbell has held various leadership roles at biopharmaceutical and chemical manufacturing companies. At Ancora Pharmaceuticals, a synthetic vaccine company, Dr. Campbell served as vice president of R&D, successfully triaging the company through its acquisition by CordenPharma. At Surface Logix and Insmed, he held senior R&D management positions and played an integral role in the discovery and development of five clinical drug candidates, including the Rho kinase inhibitor belumosudil (Rezurock™) and TAK- 607 (rIGF-1/BP-3). He earned his PhD in chemistry from Queen’s University (Canada) in 1992. He conducted post-doctoral research in natural product synthesis at Duke University during which he completed the first total synthesis of the Thy-1 GPI membrane anchor. To date, Dr. Campbell has co-authored 19 publications and is co- inventor on 23 issued patents.


Associated Grants

  • Target Validation Studies for the Discovery of Novel Small Molecule Therapeutics with the Potential to Modify Disease Outcome by Inhibiting Bacterial Amyloid Protein-induced Alpha-synuclein Aggregation and Associated Neuronal Toxicity

    2020


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.